Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Cardiac Sciences
    • 100 mg dose of...

    100 mg dose of Sitaxsentan orally once daily boosts exercise capacity and WHO FC in PAH patients with low hepatic toxicity

    Written by Deepanjana Sarkar Published On 2019-05-30T19:05:45+05:30  |  Updated On 30 May 2019 7:05 PM IST
    100 mg dose of Sitaxsentan orally once daily boosts exercise capacity and WHO FC in PAH patients with low hepatic toxicity

    A once daily dose of 100 mg of sitaxsentan may boost exercise capacity and WHO functional group in Pulmonary Arterial Hypertension (PAH) patients, pointed out a study published in the Journal of American College of Cardiology.


    Pulmonary arterial hypertension (PAH) is a progressive disorder in which endothelial dysfunction and vascular remodeling obstruct small pulmonary arteries, leading to right heart failure and ultimately death if untreated.


    Endothelin-1, a 21-amino acid peptide with a vasoconstrictor, mitogenic, and profibrotic effects play a key role in the pathobiology of PAH. Two distinct ET receptor isoforms have been identified, ET A and ET B. Endothelin A receptors are expressed on smooth muscle cells and cardiac myocytes; ET B receptors are localized on vascular endothelial cells and smooth muscle cells. Activation of ET A and ET B receptors on smooth muscle cells results in vasoconstriction, and cell proliferation and hypertrophy


    Sitaxsentan sodium is a selective ETA receptor antagonist, with high oral bioavailability and a long duration of action. Prior studies have shown improved exercise capacity (as assessed by the six-min walk [6MW] test), World Health Organization (WHO) functional class (FC), cardiac index, and pulmonary vascular resistance in 100mg-200mg of Sitaxsentan. However, the 300mg dose shown the toxicity of an unacceptable range.


    This present study aimed at ascertaining the efficacy of sitaxsentan and to determine the optimal dose on the basis of overall risk-to-benefit considerations, i.e., safety and tolerability with therapeutic efficacy.


    The authors performed a double-blind, placebo-controlled 18-week study on 247 PAH patients (idiopathic, or associated with connective tissue disease or congenital heart disease); 245 patients were treated: placebo, sitaxsentan 50 mg or 100 mg, or OL bosentan. The primary endpoint was changed in 6MW distance from the baseline to week 18. Secondary endpoints included change in WHO FC, time to clinical worsening, and change in Borg dyspnea score.


    Key findings of the study




    • At week 18, patients treated with sitaxsentan 100 mg had an increased 6MW distance compared with the placebo group, and an improved WHO FC.

    • The placebo-subtracted treatment effect for sitaxsentan 50 mg was 24.2 m and for OL bosentan, 29.5 m.

    • The incidence of elevated hepatic transaminases (>3× the upper limit of normal) was 6% for placebo, 5% for sitaxsentan 50 mg, 3% for sitaxsentan 100 mg, and 11% for bosentan.


    Based on the findings of the study the authors concluded that treatment with the selective ET A receptor antagonist sitaxsentan, orally once daily at a dose of 100 mg, improves exercise capacity and WHO FC in PAH patients, with a low incidence of hepatic toxicity.


    For further reference, please click on the link


    DOI: 10.1164/rccm.200307-957OC

    endothelial dysfunctionET BETAExercisehepatic toxicityHypertensionJACCmyocytesPAHpulmonary arterial hypertensionpulmonary arteriessitaxsentansmooth muscle cellsvascular remodelingVasoconstrictor

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Deepanjana Sarkar
    Deepanjana Sarkar
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok